Relationship between LDL-C reduction after coronary revascularization and prevention of recurrent cardiovascular events

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 2, 2010, Pages 254-262

  Nishiwaki, Tatsuhiro ^a   Kishi, Daisuke ^a   Yoshie, Fumihiko ^a   Fukuda, Keiko ^a   Ibuki, Chikao ^a   Seino, Yoshihiko ^a   Satoh, Mitsutoshi ^b  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY OBSTRUCTION; DEATH; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RECURRENT DISEASE; RESTENOSIS; RETROSPECTIVE STUDY; SECONDARY PREVENTION;

EID: 78650336877     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3hg6q     Document Type: Article

References (33)

1. Ross R, Harker L: Hyperlipidemia and atherosclerosis. Science 193: 1094-1100, 1976.
2. Ross R: Atherosclerosis-an inflammatory disease. New Engl J Med 340: 115-126, 1999.
3. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
4. Carleton RA, Dwyer J, Finberg L, Flora J, Goodman DS, Grundy SM, Havas S, Hunter GT, Kitchevsky D, Lauer RM: MRFIT research group: Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation 83: 2154-2232, 1991.
5. Nakamura Y, Yamamoto T, Okamura T, Kadowaki T, Hayakawa T, Kita Y, Saitoh S, Okayama A, Ueshima H: The NIPPON DATA 80 research group: Combined cardiovascular risk factors and outcome NIPPON DATA 80, 1980-1994. Circ J 70: 960-964, 2006.
6. Okamura T, Tanaka H, Miyamatsu N, Hayakawa T, Kadowaki T, Kita Y, Nakamura Y, Okayama A, Ueshima H: The NIPPON DATA80 research group: The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 190: 216-223, 2007.
7. Okamura T, Kadowaki K, Hayakawa T: The NIPPON DATA80 research group: What cause of mortality can we predict by cholesterol screening in the Japanese general population? Int J Med 253: 169-180, 2003.
8. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: J-LIT Study Group: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66: 1087-1095, 2002.
9. Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, itakura H: J-LIT Study Group: Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,312 Japanese hypercholesterolemic patients. Circ J 67: 287-294, 2003.
10. Horiuchi H, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: J-LIT Study Group: Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: A subanalysis of the Japan Lipid Intervention Trial. J Am Geriatr Soc 52: 1981-1987, 2004.
11. Japan Atherosclerosis Society: "The guideline for diagnosis andprevention of atherosclerotic cardiovascular diseases for Japanese 2007 edition".
12. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 43: 2142-2146, 2004.
13. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H: J-LIT study group: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease-secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT): Circ J 66: 1096-1100, 2002.
14. Scandinavian simvastatin survival study group: Randomized trial of cholesterol lowering in 4444 patient with coronary heart disease: The Scandinavia simvastatin survival study (4S). Lancet 344: 1383-1389, 1994.
15. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E: The cholesterol and, for recurrent enents trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 335: 1001-1009, 1996.
16. The long-term intervention with pravastatin in ischemic disease (LIPID) study group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349-1357, 1998.
17. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
18. Ballantyne CM: Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 82: 3Q-12Q, 1998.
19. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circ 110: 227-239, 2004.
20. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic eventsin acute coronary syndromes The MIRACL study: A sandomized controlled trial. JAMA.285: 1711-1718, 2001.
21. Thompson PL: Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients. Atheroscler suppl 2:15-9, 2001.
22. Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ: Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The pravastatin in acute coronary treatment (PACT) trial. Am Heart J 148: e2, 2004.
23. Rioufol G, Finet G, Ginon I, André-Fouët X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A: Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circ 106: 804-808, 2002.
24. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ: Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. Circ 110: 928-33, 2004.
25. Asakura M, Ueda Y, Yamaguchi O, Adachi T, Hirayama A, Hori M, Kodama K: Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: an angioscopic study. J Am Coll Cardiol 37: 1284-1288, 2001
26. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circ 104: 365-372, 2001.
27. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circ 95: 1126-1131, 1997.
28. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H: Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairmentof baseline dilator reserve. Circ 98: 1291-1296, 1998.
29. Dupuis J, Tardif J-C, Cernacek P, Théroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of cholesterol in ischemia and function of endothelium) Trial. Circ 99: 3227-3333, 1999.
30. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circ 92: 3172-3177, 1995.
31. Notarbartolo A, Davì G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa FP, Patrono C: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Bio. 15: 247-251, 1995.
32. Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, Díaz C, Hernández G, Egido J: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32: 2057-2064, 1998.
33. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circ 100: 230-235, 1999.